Race與Ardena簽署按GMP規範生產RC220的協議

By PR Newswire on 12 Jul 2023

PR Newswire (www.prnasia.com), a Cision company, is the premier global provider of media monitoring platforms and news distribution services that marketers, corporate communicators and investor relations professionals leverage to engage key audiences. Having pioneered the commercial news distribution industry since 1954, PR Newswire today provides end-to-end solutions to produce, distribute, target and measure text and multimedia content across traditional, digital, mobile and social channels. Combining the world's largest multi-channel content distribution and optimization network with comprehensive workflow tools and platforms, PR Newswire powers the stories of organizations around the world. PR Newswire serves tens of thousands of clients from offices in the Americas, Europe, Middle East, Africa and Asia-Pacific regions.

Race Oncology與全球領先的合同開發和製造組織Ardena簽署協議，後者成為按GMP規範生產bistanrene旗艦注射劑RC220的第二合作夥伴
Ardena在為各臨床開發階段提供無菌注射劑產品方面擁有悠久的歷史
此次合作增強了Race現有的生產計劃，Ardena也成為歐盟臨床研究所需的歐盟合規產品的主要供應商，為美國和澳大利亞的臨床項目提供後備供應來源。

悉尼2023年7月13日 /美通社/ -- Race Oncology Limited（以下簡稱「Race」）欣然宣佈，公司已與全球領先的合同開發和製造組織（CDMO）Ardena Holding NV（以下簡稱「Ardena」）簽署協議。根據該協議，Ardena將為Race的bisantrene旗艦靜脈注射劑RC220提供符合藥品生產質量管理規範（cGMP）的額外生產能力。